Efficacy and safety of Saroglitazar and Fenofibrate in the treatment of diabetic dyslipidaemia: A pilot study

Simple item page
dc.contributor.authorGahlot, Ren_US
dc.contributor.authorKumar, Sen_US
dc.contributor.authorGarg, Sen_US
dc.contributor.authorChawla, Sen_US
dc.contributor.authorKalra, BS.en_US
dc.date.accessioned2023-08-19T04:57:22Z
dc.date.available2023-08-19T04:57:22Z
dc.date.issued2023-03
dc.description.abstractObjectives: Diabetic dyslipidaemia (DD) is characterised by hypertriglyceridaemia and elevated or normal levels of low-density lipoprotein cholesterol and decreased levels of high-density lipoprotein cholesterol with Type 2 diabetes mellitus. Statins and anti-diabetic medication are coprescribed for optimal control. Materials and Methods: The objective of the study was to compare the safety and efficacy of Saroglitazar 4-mg and Fenofibrate 200 mg in combination with low dose Atorvastatin (10 mg) in patients with DD. Run-in period of 4 weeks for life-style and diet modification followed by 12 weeks of treatment with saroglitazar or fenofibrate and low dose of atorvastatin was followed. Primary outcome of this study was an absolute change in serum triglyceride level at baseline and end of treatment period (12 weeks). Secondary outcome was changed from baseline lipid profile, fasting blood glucose and glycosylated haemoglobin (HbA1c) at the end of treatment period. Safety assessment was also done during the duration of study. Results: Forty patients of DD were randomly divided into two groups. One group received Saroglitazar 4 mg along with Atorvastatin 10 mg. Patients in second group received Fenofibrate 200 mg along with Atorvastatin 10 mg. Improvement in deranged lipid levels in both the groups was observed and this difference in improvement statistically was not found to be significant. We also observed that Saroglitazar significantly improves glycaemic profile by decreasing fasting blood sugar levels and HbA1c (P = 0.01, P < 0.01). Adverse events reported during this study were mild and none of the patients reported serious adverse events. Conclusion: Saroglitazar could be a potential drug to control both hyperglycaemia and dyslipidaemia in patients with DD.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Maulana Azad Medical College, Delhi, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, ESIC Dental College, Delhi, Indiaen_US
dc.identifier.affiliationsDepartment of Medicine, Lok Nayak Hospital, Delhi, Indiaen_US
dc.identifier.citationGahlot R, Kumar S, Garg S, Chawla S, Kalra BS.. Efficacy and safety of Saroglitazar and Fenofibrate in the treatment of diabetic dyslipidaemia: A pilot study. Indian Journal of Physiology and Pharmacology. 2023 Mar; 67(1): 15-20en_US
dc.identifier.issn0019-5499
dc.identifier.issn2582-2799
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223972
dc.languageenen_US
dc.publisherScientific Scholar on behalf of Association of Physiologists and Pharmacologists of Indiaen_US
dc.relation.issuenumber1en_US
dc.relation.volume67en_US
dc.source.urihttps://doi.org/10.25259/IJPP_257_2022en_US
dc.subjectDiabetic dyslipidaemiaen_US
dc.subjectDyslipidemiaen_US
dc.subjectFenofibrateen_US
dc.subjectHyperlipidaemiaen_US
dc.subjectPeroxisome proliferatoractivated receptoren_US
dc.subjectSaroglitazaren_US
dc.subjectTriglyceridesen_US
dc.titleEfficacy and safety of Saroglitazar and Fenofibrate in the treatment of diabetic dyslipidaemia: A pilot studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJPP2023v67n1p15.pdf
Size:
436.5 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Physiology and Pharmacology